← Back to Search

Anti-metabolites

Chemotherapy +/− Celecoxib for Colorectal Cancer

Phase 3
Waitlist Available
Research Sponsored by Alliance for Clinical Trials in Oncology
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Node positive disease (N1 or N2) as designated in AJCC version 7
Patients with synchronous colon cancers are eligible
Must not have
Uncontrolled high blood pressure, unstable angina, history of myocardial infarction or cerebrovascular accident, New York Heart Association class III or IV heart failure
Age below 18 years
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 3 years of follow-up
Awards & highlights

Summary

This trial is studying oxaliplatin, leucovorin calcium, and fluorouracil given together with or without celecoxib in treating patients with stage III colon cancer previously treated with surgery.

Who is the study for?
This trial is for adults with stage III colon cancer that's been surgically removed. They must not have had any other cancers (with some exceptions) in the last 5 years, no severe kidney issues, and can't be pregnant or nursing. People with a history of significant gastrointestinal problems, uncontrolled high blood pressure, certain heart conditions, or allergies to platinum drugs and NSAIDs like celecoxib are excluded.Check my eligibility
What is being tested?
The study is testing if adding celecoxib (an anti-inflammatory drug) to a chemotherapy regimen of oxaliplatin, leucovorin calcium, and fluorouracil improves outcomes in patients who've had surgery for stage III colon cancer. Participants will be randomly assigned to receive either the chemo drugs alone or combined with celecoxib.See study design
What are the potential side effects?
Possible side effects include those from chemotherapy such as nausea, fatigue, nerve damage (neuropathy), low blood counts leading to increased infection risk; and from celecoxib like stomach ulcers and bleeding, allergic reactions especially in people sensitive to sulfonamides.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My cancer has spread to nearby lymph nodes.
Select...
I have more than one colon cancer at the same time.
Select...
I do not have severe nerve damage or issues with movement.
Select...
I haven't had stomach or upper intestine ulcers or bleeding in the last 3 years.
Select...
I do not have severe lung scarring or inflammation.
Select...
My colon cancer is confirmed and located above a specific area in my abdomen.
Select...
My tumor was completely removed with clear margins.
Select...
My cancer has not spread to lymph nodes or other parts of my body.
Select...
I agree to stop taking regular NSAIDs or high-dose aspirin.
Select...
I do not have serious heart conditions or uncontrolled high blood pressure.
Select...
I am 18 years old or older.
Select...
My kidney function, measured by creatinine, is within normal limits.
Select...
I have no other cancers except for certain allowed types.
Select...
I can take care of myself and am up and about more than half of my waking hours.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not have uncontrolled high blood pressure or severe heart issues.
Select...
I am under 18 years old.
Select...
My stage IV cancer was surgically removed.
Select...
I have cancer in both my colon and rectum at the same time.
Select...
I regularly use NSAIDs more than twice a week or aspirin over 325 mg at least three times a week.
Select...
I have rectal cancer.
Select...
I have moderate to severe lung scarring or inflammation.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 3 years of follow-up
This trial's timeline: 3 weeks for screening, Varies for treatment, and at 3 years of follow-up for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Disease-free Survival
Secondary outcome measures
Overall Survival

Side effects data

From undefined Phase 1 & 2 trial • 21 Patients • NCT00046839
36%
Fatigue (lethargy, malaise, asthenia)
27%
Radiation dermatitis
18%
Nausea
9%
Cough
9%
Hemoglobin (Hgb)
9%
Infection without neutropenia
9%
Pleuritic pain
9%
Weight loss
9%
Anorexia
9%
Late RT Toxicity: Lung
9%
Dysphagia-esophageal related to radiation
9%
Vomiting
9%
Edema
9%
Headache
9%
Confusion
100%
80%
60%
40%
20%
0%
Study treatment Arm
Experimental: Phase I/II: Celecoxib 400mg BID + RT
Experimental: Phase I: Celecoxib 200mg BID + RT

Trial Design

4Treatment groups
Experimental Treatment
Active Control
Group I: Arm D - FOLFOX and celecoxib (6 treatments)Experimental Treatment4 Interventions
Patients receive FOLFOX every 2 weeks plus celecoxib every day for 6 treatments (12 weeks). Each 2-week period is called a cycle. FOLFOX includes oxaliplatin, leucovorin and 5-FU.Then, patients receive celecoxib alone every day for 3 years total.
Group II: Arm B - FOLFOX and celecoxib (12 treatments)Experimental Treatment4 Interventions
Patients receive FOLFOX every 2 weeks plus celecoxib every day for 12 treatments (24 weeks). Each 2-week period is called a cycle. FOLFOX includes oxaliplatin, leucovorin and 5-FU.Then, patients receive celecoxib alone every day for 3 years total.
Group III: Arm C - FOLFOX and placebo (6 treatments)Active Control4 Interventions
Patients receive FOLFOX every 2 weeks plus placebo every day for 6 treatments (12 weeks). Each 2-week period is called a cycle. FOLFOX includes oxaliplatin, leucovorin and 5-FU.Then, patients receive placebo alone every day for 3 years total.
Group IV: Arm A - FOLFOX and placebo (12 treatments)Active Control4 Interventions
Patients receive FOLFOX every 2 weeks plus placebo every day for 12 treatments (24 weeks). Each 2-week period is called a cycle. FOLFOX includes oxaliplatin, leucovorin and 5-FU.Then, patients receive placebo alone every day for 3 years total.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
leucovorin
2005
Completed Phase 3
~1200
oxaliplatin
2002
Completed Phase 3
~6370
5-fluorouracil
2005
Completed Phase 4
~7960
celecoxib
2003
Completed Phase 3
~3010

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,748 Previous Clinical Trials
40,956,874 Total Patients Enrolled
Alliance for Clinical Trials in OncologyLead Sponsor
512 Previous Clinical Trials
215,099 Total Patients Enrolled
Jeffrey Meyerhardt, MD, MPHStudy ChairDana-Farber Cancer Institute
3 Previous Clinical Trials
335 Total Patients Enrolled

Media Library

5-fluorouracil (Anti-metabolites) Clinical Trial Eligibility Overview. Trial Name: NCT01150045 — Phase 3
Colorectal Cancer Research Study Groups: Arm C - FOLFOX and placebo (6 treatments), Arm D - FOLFOX and celecoxib (6 treatments), Arm A - FOLFOX and placebo (12 treatments), Arm B - FOLFOX and celecoxib (12 treatments)
Colorectal Cancer Clinical Trial 2023: 5-fluorouracil Highlights & Side Effects. Trial Name: NCT01150045 — Phase 3
5-fluorouracil (Anti-metabolites) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01150045 — Phase 3
~168 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top